Osimertinib after Chemoradiotherapy in Stage III <em>EGFR</em>-Mutated NSCLC

CONCLUSIONS: Treatment with osimertinib resulted in significantly longer progression-free survival than placebo in patients with unresectable stage III EGFR-mutated NSCLC. (Funded by AstraZeneca; LAURA ClinicalTrials.gov number, …